Application of BCMA CAR-T in systemic lupus erythematosus

Area of Science:

• Immunology
• Cell Therapy
• Autoimmune Diseases

Background:

• Systemic lupus erythematosus (SLE) is a complex autoimmune disorder with limited treatment options for refractory cases.
• Characterized by autoantibodies and complement activation, SLE follows a chronic relapsing-remitting course.

Purpose of the Study:

• To evaluate the feasibility, tolerability, and short-term efficacy of B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy in patients with refractory SLE.

Main Methods:

• Three female patients with refractory SLE received autologous T cells engineered with a lentiviral anti-BCMA CAR vector.
• CAR T cells were administered intravenously at a dose of 40 million cells on days 0 and 2.

Main Results:

• All patients experienced significant clinical improvement by day 13.
• Normalization of laboratory parameters was observed in all participants.
• The BCMA CAR-T cell therapy was found to be feasible and well-tolerated.

Conclusions:

• BCMA CAR-T cell therapy presents a potential new treatment strategy for systemic lupus erythematosus.
• The therapy demonstrated short-term efficacy and tolerability, warranting further clinical investigation.
• This approach offers hope for patients with treatment-resistant SLE.